Detail of the clinical trial

Title of the trial A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION
EudraCT number 2019-002491-14
Protocol number WO41535
Sponsor F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
Indications Oncology
Diagnosis HEPATOCELLULAR CARCINOMA
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 13.11.2019
Date of approval by EC 9.1.2020
Date of initiation CT in ČR 8.4.2020
Date of ending CT in ČR
Notice
Sites FN Brno,Interní hematologická a onkologická klinika,Jihlavská 20,Brno,62500
Thomayerova nemocnice,Onkologická klinika ,Vídeňská 800,Praha 4,140 59
FN Hradec Králové,Klinika onkologie a radioterapie,Sokolská 581,Hradec Králové,500 05

‹‹ Back to list